TECX

Tectonic TherapeuticD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-20

Current thesis

TECX has moved from a one-asset story toward a two-clinical-asset setup, with TX45 carrying the main upside into the 2026 APEX readout and TX2100 adding optionality after first-human dosing began in February 2026 [#8-K-2026-02-26].

Posture

Defensive

Lead driver

Momentum

What changed

Momentum remains the lead driver in the composite, 7D delta -13.4.

What can break

Earlier-than-expected financing or ATM usage if burn rises or timelines extend

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $31.00 · Bull $48.00 · Bear $16.00

Data freshness

Prices

As of 2026-07-20

Fundamentals

As of 2026-07-20 • Vendor: Data Vendor v1

Scores

As of 2026-07-20 • Model: HYBRID_IC_RP

AI Memo

As of 2026-04-15 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-20

Supporting evidence

What

Grade D · Defensive

Confidence Medium · Net Neutral

Target $78.44

Why

Momentum71 · Δ7d -13.4

Value41 · Δ7d +0.0

Sentiment41 · Δ7d +1.7

So what

Weak posture (Net Neutral). Prioritize risk control and patience.

Lead driver: Momentum · See technicals

Momentum

26% active weight

Current posture

7d trendSoftening

Δ7d

-13.4

Δ21d

-7.3

Value

39% active weight

Current posture

7d trendFlat

Δ7d

+0.0

Δ21d

-0.1

Sentiment

34% active weight

Current posture

7d trendImproving

Δ7d

+1.7

Δ21d

-3.5

Why this grade

Composite grade D. Momentum 71.0 / Value 41.1 / Sentiment 40.7

Fundamentals (TTM)

As of 2026-07-20

Market Cap

$605.14M

Beta

1.59

Shares Out

18.87M

P/E (TTM) · Derived

-7.9

P/S (TTM)

P/FCF (TTM) · Derived

-9.76

Rev YoY

EPS YoY

+44.9%

Gross Margin

Op Margin

Net Debt

-$253.11M

Current Ratio

26.63

As of 2026-07-20 • Updated nightlySource: Internal modelMethodology